Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.
2 reports, 2 independent
Updated Aug 5
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Sarepta listed on Nasdaq, gaining revenue and seeking approval status change.1 source
Sarepta faces US regulatory pause as Roche commercializes a joint treatment.1 source
Keep exploring
The entities involved
-
Sarepta
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.
- The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
Coverage
Newest first; wire copies grouped- tickerreport.com
- Investing.comSarepta stock falls after Elevidys fails to get backing by EU regulators Investing.com -- Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended again